Chen Hui, Xin Yuan, Zhou Liang, Huang Jia-meng, Tao Lei, Cheng Lei, Tian Jie
Department of Otolaryngology-Head and Neck Surgery, Affiliated Eye and ENT Hospital of Fudan University, #83, Fenyang Road, Shanghai, 200031, China.
Med Oncol. 2014 Nov;31(11):246. doi: 10.1007/s12032-014-0246-7. Epub 2014 Sep 26.
The objectives of this study were to identify specific long noncoding RNAs (lncRNAs) in laryngeal squamous cell carcinoma (LSCC) and to clarify the function of cisplatin and paclitaxel on the confirmed laryngeal cancer lncRNAs. Fifty-four pairs of laryngeal tumor and adjacent normal tissue were collected. Candidate lncRNAs were searched in authorized databases. The significant lncRNAs were identified and confirmed through high-output real-time PCR. Chemotherapy assay evaluated the influences of cisplatin and paclitaxel on the significant lncRNAs. Thirty-seven cancer-related candidate lncRNAs were selected. Three up-expressed and two down-expressed significant lncRNAs were identified and confirmed. The expressions of lncRNA CDKN2B-AS1, HOTAIR and MALAT1 were dramatically reduced with the increasing concentration of cisplatin and paclitaxel and also lengthening of the treatment duration. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs.
本研究的目的是鉴定喉鳞状细胞癌（LSCC）中特定的长链非编码RNA（lncRNA），并阐明顺铂和紫杉醇对已确认的喉癌lncRNA的作用。收集了54对喉肿瘤组织和相邻正常组织。在权威数据库中搜索候选lncRNA。通过高产量实时PCR鉴定并确认显著的lncRNA。化疗试验评估了顺铂和紫杉醇对显著lncRNA的影响。选择了37个与癌症相关的候选lncRNA。鉴定并确认了3个上调和2个下调的显著lncRNA。随着顺铂和紫杉醇浓度的增加以及治疗时间的延长，lncRNA CDKN2B-AS1、HOTAIR和MALAT1的表达显著降低。顺铂和紫杉醇对LSCC中的显著lncRNA具有靶向作用，这为治疗LSCC患者提供了新的分子靶点，也为开发新药指明了方向。
